Concert Pharmaceuticals, Inc. / Fundamentals
Income statement
- Net revenue
€48.26K - Cost of goods sold
€0.00 - Gross profit
€48.26K - SG&A expenses
€8.57M - R&D expenses
€48.80M - EBITDA
-€58.51M - D&A
€110.88K - EBIT
-€58.62M - Interest expenses
€1.45M - EBT
-€57.65M - Tax expenses
-€3.68M - Net income
-€56.68M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€47.02M - Changes in working capital
€2.60M - Operating cash flow
-€93.54M - Capex
€239.68K - Other investing cash flow
€0.00 - Net investing cash flow
-€46.17M - Total cash dividends paid
€0.00 - Issuance of common stock
€96.22M - Debt repayment
€0.00 - Other financing cash flow
€132.48M - Net financing cash flow
€132.48M - Foreign exchange effects
€0.00 - Net change in cash
-€7.23M - Cash at end of period
€82.18M - Free cash flow
-€93.30M
Balance sheet
- Cash and cash equivalents
€81.19M - Cash and short-term investments
€127.54M - Total receivables
€1.41M - Inventory
€0.00 - Other current assets
€5.13M - Total current assets
€134.08M - Property, plant & equipment
€10.90M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€986.86K - Total non-current assets
€11.89M - Total assets
€145.97M - Accounts payable
€2.34M - Short-term debt
€1.15M - Other current liabilities
€4.87M - Total current liabilities
€14.84M - Long-term debt
€10.98M - Deferred tax liabilities
-€6.48M - Other non-current liabilities
€6.48M - Total non-current liabilities
€17.45M - Total liabilities
€32.29M - Common stock
€38.38K - Retained earnings
-€375.34M - Other equity
-€114.30K - Total equity
€113.67M - Total liabilities and shareholders' equity
€145.97M
Company information
- Market capitalization
€0.00 - Employees
64 - Enterprise Value
-€126.57M
Company ratios
- Gross margin
-
100.0% Much worse than peer group: 130.1% - EBITDA margin
-
-121,245.1% Much worse than peer group: -7,482.6% - EBIT margin
-
-121,474.9% Much worse than peer group: -7,287.7% - EBT margin
-
-119,465.3% Much worse than peer group: -5,011.4% - Net margin
-
-117,455.6% Much worse than peer group: -5,376.0% - ROE
-
-49.9% Much worse than peer group: 371.3% - ROA
-
-38.8% Much better than peer group: -433.6% - Asset turnover
-
0.0% Much worse than peer group: 267.1% - FCF margin
-
-194,322.9% Much worse than peer group: -6,087.6% - FCF yield
0.0% - Efficiency ratio
121,345.1% - Net sales per employee
-
€754.04 - Net income per employee
-
-€885.66K